2. Academic Validation
  3. Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries

Discovery of a novel small molecule degrader of wild type and mutant estrogen receptors using DNA encoded libraries

  • NPJ Breast Cancer. 2025 Nov 12;11(1):125. doi: 10.1038/s41523-025-00837-5.
Anil Kumar Devakrishnan 1 2,  Chandrashekhar Madasu 1 2,  Yong Wang 1 2,  Ramkumar Modukuri 1 2,  Kurt M Bohren 1 2,  Kevin R MacKenzie 1 2 3,  Damian W Young 1 2 3,  Suzanne A W Fuqua 4 5 6,  Martin M Matzuk 1 2 3,  Murugesan Palaniappan 7 8 9
Affiliations

Affiliations

  • 1 Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA.
  • 2 Center for Drug Discovery, Baylor College of Medicine, Houston, TX, USA.
  • 3 Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, USA.
  • 4 Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
  • 5 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
  • 6 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
  • 7 Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA. palaniap@bcm.edu.
  • 8 Center for Drug Discovery, Baylor College of Medicine, Houston, TX, USA. palaniap@bcm.edu.
  • 9 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. palaniap@bcm.edu.
PMID: 41224743 DOI: 10.1038/s41523-025-00837-5
Abstract

Estrogen receptor α (ERα) variants with mutations in the ligand binding domain (LBD) are less sensitive than wild type to standard-of-care drugs that bind ERα directly. To identify novel small-molecule drugs that target ERα mutants, we screened our multibillion-compound DNA-encoded libraries against ERα LBD variants. CDD-1274, which was highly enriched with all three variants, blocked spontaneous coactivator peptide recruitment to mutant ERα LBDs and inhibited estradiol-driven proliferative markers in several ER-positive breast Cancer cell lines, but not in ER-negative breast Cancer cells. We demonstrated that CDD-1274 induced proteasomal degradation of ERα variants in breast Cancer cell lines and caused Y537S ERα degradation more effectively than elacestrant in a palbociclib-resistant cell line. These findings establish that CDD-1274 potently blocks ligand-dependent and ligand-independent ER signaling in endocrine-resistant breast Cancer cells and could be further optimized for developing a new class of ERα degraders for endocrine therapy-resistant breast Cancer.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z